Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 51

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2017

Summary

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2017, outlays comprehensive information on the Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - 65-kDa cytosolic phosoprotein (pp65) counteracts the host antiviral immune response when activated and phosphorylated and by preventing IRF3 from entering the nucleus. It participates in the transactivation of viral major immediate-early genes by the recruitment of host IFI16 to the promoter pf these genes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 3, 1, 2 and 2 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Immunology which include indications Cytomegalovirus (HHV-5) Infections, Glioblastoma Multiforme (GBM), Brain Tumor, Hematological Tumor, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Transplant Rejection and Liver Transplant Rejection.

Furthermore, this report also reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)

- The report reviews Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics and enlists all their major and minor projects

- The report assesses Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2017

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Overview 6
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 12
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Assessment 14
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Companies Involved in Therapeutics Development 18
Astellas Pharma Inc 18
Hookipa Biotech AG 18
Immunomic Therapeutics Inc 18
Vakzine Projekt Management GmbH 19
Vaximm AG 19
VBI Vaccines Inc 20
Vical Inc 20
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Drug Profiles 21
ASP-0113 - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Cellular Immunotherapy to Target PP65 for Glioblastoma Multiforme - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
CyMVectin - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
HB-101 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
PepVax - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Triplex - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
VBI-1901 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
VPM-2001 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
VXM-65 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Dormant Products 38
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Discontinued Products 39
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Product Development Milestones 40
Featured News & Press Releases 40
Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit 40
Aug 15, 2017: VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme 40
May 04, 2017: Hookipa Biotech Presents Positive Data from Phase 1 First-In-Human Trial of Vaccine Against Cytomegalovirus 41
Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress 41
Jan 09, 2017: Hookipa Biotech Announces Publication in Clinical and Vaccine Immunology Highlighting Vaxwave as an Effective Viral Vector for Vaccination against Congenital Cytomegalovirus Infections 42
Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting 42
Oct 28, 2016: Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in Blood 43
Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate 44
Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe 44
Sep 20, 2016: Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus Vaccine (ASP0113) in Kidney Transplant Patients 45
Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit 45
Jul 20, 2016: Hookipa Biotech Initiates First-in-Human Study of Cytomegalovirus Vaccine 46
Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program 46
Mar 29, 2016: VBI To Present At The World Vaccine Congress Washington 47
Mar 07, 2016: VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products under Investigation by Universities/Institutes, H2 2017 12
Products under Investigation by Universities/Institutes, H2 2017 13
Number of Products by Stage and Route of Administration, H2 2017 15
Number of Products by Stage and Molecule Type, H2 2017 17
Pipeline by Astellas Pharma Inc, H2 2017 18
Pipeline by Hookipa Biotech AG, H2 2017 18
Pipeline by Immunomic Therapeutics Inc, H2 2017 19
Pipeline by Vakzine Projekt Management GmbH, H2 2017 19
Pipeline by Vaximm AG, H2 2017 19
Pipeline by VBI Vaccines Inc, H2 2017 20
Pipeline by Vical Inc, H2 2017 20
Dormant Projects, H2 2017 38
Discontinued Products, H2 2017 39

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Routes of Administration, H2 2017 14
Number of Products by Stage and Routes of Administration, H2 2017 14
Number of Products by Molecule Types, H2 2017 16
Number of Products by Stage and Molecule Types, H2 2017 16
  • Global Gene Synthesis Sales Market Report 2017
    Published: 23-Nov-2017        Price: US 4000 Onwards        Pages: 111
    In this report, the global Gene Synthesis market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Gene Synthesis for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - ......
  • United States Microbial Growth Media Market Report 2017
    Published: 22-Nov-2017        Price: US 3800 Onwards        Pages: 100
    In this report, the United States Microbial Growth Media market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth r......
  • Global Laser Capture Microdissection Market Professional Survey Report 2017
    Published: 22-Nov-2017        Price: US 3500 Onwards        Pages: 108
    This report studies Laser Capture Microdissection in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Leica Microsystems - Thermo Fisher Scientific - Carl Zeiss......
  • Global Biotechnology Separation Systems Market Research Report 2017
    Published: 22-Nov-2017        Price: US 2900 Onwards        Pages: 114
    In this report, the global Biotechnology Separation Systems market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Biotechnology Separation Systems in these regions, from 2012 to 2022 (forecast), covering - North America - ......
  • Asia-Pacific Laser Capture Microdissection Market by Manufacturers, Regions, Type and Application, Forecast to 2022
    Published: 22-Nov-2017        Price: US 4480 Onwards        Pages: 120
    Laser Capture Microdissection (LCM) technology is a contagion free process for obtaining sub-populations of tissue cells under direct microscopic apparition. In addition, laser-capture Microdissection technology isolates specific cells by dissecting unwanted cells. Laser Capture Microdissection technology harvests the cells of attention straight to give pure enriched cells. This technology helps in preserving the genuine morphology of the dissected cell or tissue sample. The Laser Capture Microd......
  • Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H2 2017
    Published: 21-Nov-2017        Price: US 3500 Onwards        Pages: 43
    Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Tumor necrosis factor receptor superfamily member 6 (TNFRSF6) is a protein encoded by the TNFRSF6 gene. It acts as a receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. FAS-mediated apoptosis plays an important role in the induction of peripheral tolerance in the antigen-stimulated suicide of ma......
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017
    Published: 21-Nov-2017        Price: US 3500 Onwards        Pages: 49
    According to the recently published report 'T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017'; T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the producti......
  • Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H2 2017
    Published: 21-Nov-2017        Price: US 3500 Onwards        Pages: 30
    Human Papillomavirus Minor Capsid Protein L2 (L2) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H2 2017, outlays comprehensive information on the Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of acti......
  • Interleukin 1 (IL1) - Pipeline Review, H2 2017
    Published: 21-Nov-2017        Price: US 3500 Onwards        Pages: 106
    Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity.Interleukin 1 (IL1)......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs